- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ENZOLYTICS Aktie jetzt für 0€ handeln | |||||
| 18.09.24 | Enzolytics, Inc.: Bulgarian Academy of Sciences Issues Report on Results of Its In Vivo Testing of IPF as an Immunomodulator | 364 | ACCESS Newswire | FIRST COLLABORATIVE EFFORT UNDER NEW AGREEMENT ALLEN, TX / ACCESSWIRE / September 18, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the "Company") announced today that the Department of... ► Artikel lesen | |
| 09.09.24 | Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences and Enzolytics, Inc. Execute Three Year Agreement | 511 | ACCESS Newswire | ALLEN, TX / ACCESSWIRE / September 9, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the "Company") announced today that the Company and the Stephan Angeloff Institute of Microbiology,... ► Artikel lesen | |
| 20.08.24 | Enzolytics, Inc.: Final Report From the National Centre of Infectious and Parasitic Diseases Concludes Lyophilized Pepsin Significantly Reduces the Survival and Proliferation of Growth in Specific Cancer Cells | 365 | ACCESS Newswire | ALLEN, TX / ACCESSWIRE / August 20, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the "Company") announced today that a study conducted at the Ministry of Health National Centre of Infectious... ► Artikel lesen | |
| 31.07.24 | Enzolytics, Inc. and the Bulgarian Academy of Sciences Initiate a Cooperative Program Primarily Focusing on Applied and Strategic Research in Immunology for Cancer and HIV/AIDS Applications | 520 | ACCESS Newswire | As well as Diabetes, Multiple Sclerosis and Other Diseases ALLEN, TX / ACCESSWIRE / July 31, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the "Company") announced today that the Company... ► Artikel lesen | |
| 29.07.24 | Enzolytics, Inc. Enters Into Collaboration Agreement With Manufacturer Elimus Ltd. | 283 | ACCESS Newswire | Updates on Results of Litigation ALLEN, TX / ACCESSWIRE / July 29, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com")(the "Company") announced today that it has entered into a 4 year Collaboration... ► Artikel lesen | |
| 26.07.24 | Enzolytics, Inc.: Enzolytics Inc. Supports Sagaliam Acquisition Corp Response to Competitors False and Misleading Press Release | 618 | ACCESS Newswire | ALLEN, TX / ACCESSWIRE / July 26, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) (enzolytics.com) (the "Company") stated today that the Company will whole heartedly support any and all efforts by Sagaliam... ► Artikel lesen | |
| 01.07.24 | Enzolytics, Inc. Enters Into Exclusive Worldwide License for Patented Immunotherapy Cancer Treatment | 337 | ACCESS Newswire | Update on Sagaliam Acquisition Corp. ALLEN, TX / ACCESSWIRE / July 1, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the "Company") announced today that the Company is entering into a worldwide... ► Artikel lesen | |
| 03.06.24 | Enzolytics, Inc. Poised to Invest Alongside Sagaliam Acquisition Corp in Revolutionary Room Temperature SPAD Technology | 426 | ACCESS Newswire | ALLEN, TX / ACCESSWIRE / June 3, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com")(the "Company") is thrilled to announce that the Company and Sagaliam Acquisition Corp ("SAGA") are negotiating... ► Artikel lesen | |
| 22.05.24 | Enzolytics, Inc. Announces Letter of Intent for Exclusive Licensing Agreement for Patented Nitric Oxide Formulation | 417 | ACCESS Newswire | Updates on ETC Marketing, Inc and Ownership of ITV-1 and IPFALLEN, TX / ACCESSWIRE / May 22, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com")(the "Company") announced today that it has entered... ► Artikel lesen | |
| 02.05.24 | Enzolytics, Inc. Announces Formation of Marketing Company in Partnership with Third Coast Fulfillment | 368 | ACCESS Newswire | ALLEN, TX / ACCESSWIRE / May 2, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) (the "Company") announced today the plan to form ETC Marketing Inc. ("ETC Marketing") in partnership with Third Coast Fulfillment... ► Artikel lesen | |
| 26.04.24 | Sagaliam Acquisition Corp. Announces Novation Agreement with Enzolytics, Inc. | 623 | ACCESS Newswire | NEW YORK, NY / ACCESSWIRE / April 26, 2024 / Sagaliam Acquisition Corp. ("SAGAU", "SAGA", SAGAR") (the "Company") announced that Sagaliam entered into a Novation Agreement with Enzolytics, Inc. (OTC... ► Artikel lesen | |
| 23.04.24 | Enzolytics, Inc.: Enzolytics Inc. Announces Dismissal of The Dimitar Savov Lawsuit in Nevada | 383 | ACCESS Newswire | Offers Update on OTC Annual Report and Business Model ALLEN, TX / ACCESSWIRE / April 23, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) (enzolytics.com)(the "Company") today disclosed that on April 9, 2024... ► Artikel lesen | |
| 12.04.24 | Enzolytics, Inc.: Update on Formulation of New Business Strategy | 540 | ACCESS Newswire | INFORMATION ON ENZOLYTICS, INC.BOARD OF DIRECTORS AND CHIEF EXECUTIVE OFFICERUPDATE ON FORMULATION OF NEW BUSINESS STRATEGYALLEN, TX / ACCESSWIRE / April 12, 2024 / Enzolytics, Inc. (OTC PINK:ENZC)... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 36,310 | +3,08 % | EQS-Adhoc: QIAGEN N.V.: QIAGEN kündigt starkes vorläufiges Ergebnis im ersten Quartal 2025 an und hebt die Prognose für den bereinigten Gewinn je Aktie für das Gesamtjahr 2025 | EQS-Ad-hoc: QIAGEN N.V. / Schlagwort(e): Vorläufiges Ergebnis
QIAGEN N.V.: QIAGEN kündigt starkes vorläufiges Ergebnis im ersten Quartal 2025 an und hebt die Prognose für den bereinigten Gewinn... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 36,470 | +5,93 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates | - Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively - - Received FDA approval of GOMEKLI (mirdametinib)... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 46,430 | +5,14 % | Tarsus Pharmaceuticals, Inc: Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care | Advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, another large, underserved eye disease with no FDA-approved therapy; Initiation of Phase 2 study planned for... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,745 | +27,38 % | Recursion Pharmaceuticals: Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas | Salt Lake City, UT, April 08, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first... ► Artikel lesen | |
| TEMPUS AI | 42,120 | +4,54 % | Tempus AI vs. Doximity: Which AI in Healthcare Stock is a Better Buy? | ||
| EVOTEC | 5,354 | -0,48 % | Bayer, BioNxt Solutions, Evotec - falscher Zoll Alarm bei Pharma und Biotech! Welche Aktien lohnen sich? | Die vorläufige Zollausnahme für Medikamente und pharmazeutische Produkte bietet der Branche eine Atempause - doch der Schein trügt. Gestützt auf WTO-Regeln schützen die Ausnahmen zwar deutsche Exporte... ► Artikel lesen | |
| BIONTECH | 82,70 | +0,98 % | BioNTech-Aktie: Wie im Vollrausch! | News von Trading-Treff.de BioNTech ist inzwischen massiv auf dem Weg nach unten. An der US Börse NASDAQ hat das Papier gestern einen Abschlag in Höhe von 4,3 % hinnehmen müssen. In Deutschland ist die... ► Artikel lesen | |
| PORTAGE BIOTECH | 8,270 | +53,72 % | Portage Biotech Shares Soar 94% | ||
| SUMMIT THERAPEUTICS | 23,230 | +15,29 % | Why Summit Therapeutics Inc. (SMMT) Went Up On Thursday? | ||
| KINIKSA PHARMACEUTICALS | 19,310 | +3,54 % | Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy | - Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025 - - KPL-387 Phase 1 single ascending dose data support potential monthly dosing - - Kiniksa... ► Artikel lesen | |
| ARCELLX | 59,14 | +4,38 % | Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 13,400 | +9,75 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's ... | - Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 12,580 | -6,40 % | Arcutis Biotherapeutics, Inc.: Arcutis Announces Chief Financial Officer Transition | WESTLAKE VILLAGE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen | |
| IMMUNOVANT | 14,700 | -0,61 % | Immunovant Inc.: Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies | Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 15,900 | +5,65 % | Leerink cuts Structure Therapeutics target to $60, keeps outperform |
Das Unternehmen ENZOLYTICS INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ENZOLYTICS INC finden Sie auf Wallstreet Online.
